Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches
Carla Navarro,
Ángel Ortega,
Raquel Santeliz,
Bermary Garrido,
Maricarmen Chacín,
Néstor Galban,
Ivana Vera,
Juan Bautista De Sanctis,
Valmore Bermúdez
Affiliations
Carla Navarro
Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4004, Venezuela
Ángel Ortega
Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4004, Venezuela
Raquel Santeliz
Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4004, Venezuela
Bermary Garrido
Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4004, Venezuela
Maricarmen Chacín
Universidad Simón Bolívar, Facultad de Ciencias de la Salud, Barranquilla 080002, Colombia
Néstor Galban
Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4004, Venezuela
Ivana Vera
Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4004, Venezuela
Juan Bautista De Sanctis
Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Czech Advanced Technology and Research Institute, Palacký University Olomouc, 779 00 Olomouc, Czech Republic
Valmore Bermúdez
Universidad Simón Bolívar, Facultad de Ciencias de la Salud, Barranquilla 080002, Colombia
The constant changes in cancer cell bioenergetics are widely known as metabolic reprogramming. Reprogramming is a process mediated by multiple factors, including oncogenes, growth factors, hypoxia-induced factors, and the loss of suppressor gene function, which support malignant transformation and tumor development in addition to cell heterogeneity. Consequently, this hallmark promotes resistance to conventional anti-tumor therapies by adapting to the drastic changes in the nutrient microenvironment that these therapies entail. Therefore, it represents a revolutionary landscape during cancer progression that could be useful for developing new and improved therapeutic strategies targeting alterations in cancer cell metabolism, such as the deregulated mTOR and PI3K pathways. Understanding the complex interactions of the underlying mechanisms of metabolic reprogramming during cancer initiation and progression is an active study field. Recently, novel approaches are being used to effectively battle and eliminate malignant cells. These include biguanides, mTOR inhibitors, glutaminase inhibition, and ion channels as drug targets. This review aims to provide a general overview of metabolic reprogramming, summarise recent progress in this field, and emphasize its use as an effective therapeutic target against cancer.